90 related articles for article (PubMed ID: 1922575)
1. Prognostic value of the epithelial membrane antigen (EMA) in the case of Hodgkin's disease.
Touhami H; Sotto JJ; Sotto MF; Couderc P; Keddari E; Brahimi S; Kubisz P
Neoplasma; 1991; 38(4):433-7. PubMed ID: 1922575
[TBL] [Abstract][Full Text] [Related]
2. Malignant pleural effusion in Hodgkin's lymphoma. Report of a case with immunoperoxidase studies.
Peterson IM; Raible M
Acta Cytol; 1991; 35(3):300-5. PubMed ID: 1710403
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of phenotyping by Ber-H2, Leu-M1, EMA in Hodgkin's disease.
de Mascarel I; Trojani M; Eghbali H; Coindre JM; Bonichon F
Arch Pathol Lab Med; 1990 Sep; 114(9):953-5. PubMed ID: 1975165
[TBL] [Abstract][Full Text] [Related]
4. [Is irradiation of intact ileoinguinal lymph nodes necessary in radiochemotherapy for stage-III Hodgkin's disease?].
Kanaev SV; Girshovich MM; Golovanov SG; Gershanovich ML
Vopr Onkol; 2007; 53(4):453-5. PubMed ID: 17969410
[TBL] [Abstract][Full Text] [Related]
5. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
6. [Clinical evaluation of combined treatment of stage III(B) Hodgkin's disease].
Kanaev SV; Golovanov SG; Girshovich MM; Gershanovich ML
Vopr Onkol; 2006; 52(5):525-30. PubMed ID: 17168360
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy of early stages Hodgkin's disease. 10 years experience of the Masaryk Memorial Cancer Institute.
Petera J; Macharová H; Pohanková R; Malír A; Coupek P; Konecný M; Patera J; Pecina J; Drbal J; Koukalová H; Vásová I
Neoplasma; 2000; 47(2):129-32. PubMed ID: 10985481
[TBL] [Abstract][Full Text] [Related]
8. [A retrospective analysis of the treatment results in Hodgkin's disease in a radiotherapy clinic].
Mjaaland I; Ganser D; Freitag EM; Bohndorf W
Strahlenther Onkol; 1994 Sep; 170(9):516-23. PubMed ID: 7524173
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution.
Smolewski P; Robak T; Krykowski E; Blasiñska-Morawiec M; Niewiadomska H; Pluzanska A; Chmielowska E; Zambrano O
Clin Cancer Res; 2000 Mar; 6(3):1150-60. PubMed ID: 10741746
[TBL] [Abstract][Full Text] [Related]
10. Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy.
Muwakkit S; Geara F; Nabbout B; Farah RA; Shabb NS; Hajjar T; Khogali M
Radiat Oncol Investig; 1999; 7(6):365-73. PubMed ID: 10644060
[TBL] [Abstract][Full Text] [Related]
11. [Influence of age on treatment results in children and adolescents with Hodgkin's disease].
Balwierz W; Moryl-Bujakowska A; Depowska T; Klekawka T; Stanuch H; Matysiak M; Sopyło B; Kołakowska-Mrozowska B; Krenke K; Chybicka A; Raś M; Sońta-Jakimczyk D; Moszant A; Wachowiak J; Kaczmarek-Kanold M; Kowalczyk J; Odój T; Balcerska A; Drozyńska E; Wysocki M; Kołtan A; Krawczuk-Rybak M; Stolarska M
Przegl Lek; 2004; 61 Suppl 2():40-4. PubMed ID: 15686044
[TBL] [Abstract][Full Text] [Related]
12. Hodgkin's disease and CD30-positive anaplastic large cell lymphomas--a continuous spectrum of malignant disorders. A quantitative morphometric and immunohistologic study.
Leoncini L; Del Vecchio MT; Kraft R; Megha T; Barbini P; Cevenini G; Poggi S; Pileri S; Tosi P; Cottier H
Am J Pathol; 1990 Nov; 137(5):1047-57. PubMed ID: 2173409
[TBL] [Abstract][Full Text] [Related]
13. Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications.
Koontz BF; Kirkpatrick JP; Clough RW; Prosnitz RG; Gockerman JP; Moore JO; Prosnitz LR
J Clin Oncol; 2006 Feb; 24(4):605-11. PubMed ID: 16446333
[TBL] [Abstract][Full Text] [Related]
14. [Clinical evaluation of efficacy of chemoradiotherapy for Hodgkin's disease].
Kanaev SV; Gershanovich ML; Pozharisskiĭ KM; Girshovich MM; Malinin AP; Golovanov SG
Vopr Onkol; 2004; 50(6):652-7. PubMed ID: 15755057
[TBL] [Abstract][Full Text] [Related]
15. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.
Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W
Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984
[TBL] [Abstract][Full Text] [Related]
16. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
Wheeler C; Eickhoff C; Elias A; Ibrahim J; Ayash L; McCauley M; Mauch P; Schwartz G; Eder JP; Mazanet R; Ferrara J; Rimm IJ; Guinan E; Bierer B; Gilliland G; Churchill WH; Ault K; Parsons S; Antman K; Schnipper L; Tepler I; Gaynes L; Frei E; Kadin M; Antin J
Biol Blood Marrow Transplant; 1997 Jun; 3(2):98-106. PubMed ID: 9267670
[TBL] [Abstract][Full Text] [Related]
17. Don't throw out the baby with the bathwater: on optimizing cure and reducing toxicity in Hodgkin's lymphoma.
Yahalom J
J Clin Oncol; 2006 Feb; 24(4):544-8. PubMed ID: 16446326
[No Abstract] [Full Text] [Related]
18. Significance of cell proliferation index in assessing histological prognostic categories in Hodgkin's disease. An immunohistochemical study with Ki67 and MIB-1 monoclonal antibodies.
Abele MC; Valente G; Kerim S; Navone R; Onesti P; Chiusa L; Resegotti L; Palestro G
Haematologica; 1997; 82(3):281-5. PubMed ID: 9234572
[TBL] [Abstract][Full Text] [Related]
19. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
[TBL] [Abstract][Full Text] [Related]
20. [Use of risk-adapted programs of treatment of Hodgkin's disease in children and adolescents].
Kuleva SA
Vopr Onkol; 2008; 54(6):768-70. PubMed ID: 19241857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
